News & Events

In the news

Clean Mails – June 2023

Integrated solutions for cell and virus bank manufacturing and characterization

As a GMP-licensed organization, Clean Cells has a stellar track record in biosafety testing and characterization services for various biopharmaceuticals since 2000. Moreover, the company excels in cell and virus bank manufacturing services to produce starting materials for vaccines, monoclonal antibodies, cell and gene therapies, and other biological products for human and animal health.

Clean Mails – April 2023

A new facility to extend biopharma services

Last January, Clean Cells opened its new cGMP-compliant facility, a cutting-edge 5 300 m2 platform which considerably extends biopharma capacities. Additional biologics testing capacity, extended cell and gene therapy services, end-to-end biomanufacturing and storage: Clean Cells’ new site opens a new chapter in the company’s rich history.

Save the date !

Congresses 2023: meet our teams!

Teams at Clean Cells are traveling the world to attend major conferences and congresses within the biotech sector. As leaders of the biopharma field, our mission and our drive at the Clean Biologics group are to remain both reachable and up-to-date with regards to the latest developments and innovations.

Press Release

Clean Cells launches activities at new biopharmaceutical quality control facility - largest in Europe

With 5,300m2 of new premises, €22M building offers four times more laboratory space than previous facility


Opening of the New Facilities - 12 January 2023

On Thursday, January 12, 2023, Clean Cells celebrated the opening of its new facilities! It was the occasion to gather our staff and ex-staff, our sister companies Naobios & Biodextris, our shareholders, our local customers, our partners, the local authorities, the companies & banks that contributed to the achievement of this beautiful project...

Press Release

Clean Cells inaugure son nouveau site d’analyse et de production biopharmaceutique

Le laboratoire de 5 300m2 permettra de multiplier par quatre les capacités d’analyse et de production du groupe, devenant ainsi le plus grand site de contrôle qualité des médicaments biopharmaceutiques et de production de banques de cellules pour les médicaments innovants en Europe.